Skip to content

Tadalafil

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used to treat erectile dysfunction and benign prostatic hyperplasia. It works by increasing blood flow to certain areas of the body, which can improve sexual function and potentially have cardiovascular benefits. Its role in longevity and health optimization is linked to improved vascular health and circulation.

Intelligence Profile

Clinical Applications

Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor primarily used in the treatment of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and certain cases of pulmonary hypertension. Its clinical applications are supported by various studies and trials:

  1. Erectile Dysfunction (ED):
    Tadalafil is highly effective in treating erectile dysfunction. A systematic review and network meta-analysis highlight its efficacy as part of medical interventions for ED after prostate cancer treatment (PMID: 42557727). Clinical trials (e.g., NCT00931528 and NCT07602608) also explore its use in preventing and treating ED, even when supplemented with therapies like platelet-rich plasma.

  2. Lower Urinary Tract Symptoms (LUTS) due to BPH:
    Tadalafil is used to manage lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS), improving symptoms and quality of life (NCT02431754). It has shown positive effects on endothelial, angiogenic, and metabolic profiles in men with BPH and ED (PMID: 42538422).

  3. Pulmonary Hypertension:
    Tadalafil targets the NO-sGC-cGMP pathway and has therapeutic efficacy in treating chronic thromboembolic pulmonary hypertension (PMID: 42516671).

  4. Prevention of Erectile Dysfunction Post-Treatment:
    Clinical trials have investigated its role in preventing ED following radiation therapy in prostate cancer patients (NCT00931528), extending its application beyond immediate symptoms to prophylactic use.

  5. Peyronie's Disease:
    A review suggests that active Peyronie's disease could be an early treatment window with antifibrotic potential, although further specific implications of tadalafil in this context require more evidence (PMID: 42564900).

  6. Duchenne Muscular Dystrophy:
    An early-phase trial (NCT01359670) explored tadalafil alongside sildenafil in managing Duchenne Muscular Dystrophy, though its direct clinical benefits in this area are less established.

Additional Considerations:
The risk of glaucoma when using tadalafil for LUTS has been examined, though the implications are still being explored (PMID: 42552102).

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for treatment decisions.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.